The results of the meta‐analysis revealed a significant association between LAPTM4B polymorphism and cancer susceptibility cancer in codominant (OR = 1.42, 95% CI = 1.27‐1.59, P < 0.00001, *1/2 vs *1/1; OR = 2.01, 95% CI = 1.69‐2.39, P < 0.00001, *2/2 vs *1/1), dominant (OR = 1.50, 95% CI = 1.34‐1.69, P < 0.00001, *1/2 + *2/2 vs *1/1), recessive (OR = 1.73, 95% CI = 1.53‐1.95, P < 0.00001, *2/2 vs *1/1 + *1/2), overdominant (OR = 1.28, 95% CI = 1.17‐1.41, P < 0.00001, *1/2 vs *1/1 + *2/2), and allele (OR = 1.40, 95% CI = 1.28‐1.53, P < 0.00001, *2 vs *1) inheritance model tested (Figure 1). This evidence concerns the gene LAPTM4B and cancer.